Logo.png
Marginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period (2019–2032), Analysis by DelveInsight
12. Oktober 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Marginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period (2019–2032), Analysis by DelveInsight  ...
Logo.png
40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight
21. September 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- 40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight Marginal Zone Lymphoma Pipeline constitutes 40+...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
19. Februar 2019 16:30 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...